Age, Biography and Wiki
Didier Trono was born on 1956. Discover Didier Trono's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is He in this year and how He spends money? Also learn how He earned most of networth at the age of 67 years old?
| Popular As |
N/A |
| Occupation |
N/A |
| Age |
67 years old |
| Zodiac Sign |
|
| Born |
1956 |
| Birthday |
1956 |
| Birthplace |
N/A |
| Nationality |
|
We recommend you to check the complete list of Famous People born on 1956.
He is a member of famous with the age 67 years old group.
Didier Trono Height, Weight & Measurements
At 67 years old, Didier Trono height not available right now. We will update Didier Trono's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family |
| Parents |
Not Available |
| Wife |
Not Available |
| Sibling |
Not Available |
| Children |
Not Available |
Didier Trono Net Worth
His net worth has been growing significantly in 2022-2023. So, how much is Didier Trono worth at the age of 67 years old? Didier Trono’s income source is mostly from being a successful . He is from . We have estimated
Didier Trono's net worth
, money, salary, income, and assets.
| Net Worth in 2023 |
$1 Million - $5 Million |
| Salary in 2023 |
Under Review |
| Net Worth in 2022 |
Pending |
| Salary in 2022 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
|
Didier Trono Social Network
| Instagram |
|
| Linkedin |
|
| Twitter |
|
| Facebook |
|
| Wikipedia |
|
| Imdb |
|
Timeline
In 2016, Trono cofounded the Health 2030 initiative, a Swiss multicentric and multidisciplinary program which aims at promoting the development and exploitation of new technologies in the field of health and personalized medicine.
Trono was awarded with two Advanced Grants from the European Research Council in 2010 and 2015 for projects on mammalian gene regulation by KRAB proteins and transposable elements. He also received a Proof of Concept grant in 2016 for the development of a novel diagnostic method based on the analysis of transposable elements.
In 2002, Trono was awarded the Leenaards Scientific Prize for his contributions to the understanding of the genetic factors of vulnerability towards HIV infections.
Trono obtained an M.D. from the University of Geneva in 1982 and completed a clinical training in internal medicine, pathology and infectious diseases in Geneva and at the Massachusetts General Hospital, Boston. Trono started his scientific career in 1986 when he joined David Baltimore's laboratory at the Whitehead Institute for Biomedical Research as a postdoctoral researcher, where he studied the molecular mechanisms linked to poliovirus and HIV pathogenesis. In 1990, he was appointed assistant professor at the Salk Institute for Biological Studies, where he founded a center for AIDS research. There, he notably contributed to the understanding of why HIV specifically infects human T helper cells, and developed a new class of gene therapy vectors based on HIV capable of infecting non-dividing cells that have since then been widely used in clinical and research settings. In 1997, he was appointed full professor at the University of Geneva, where he was named head of the Department of Genetics and Microbiology in 2000. In 2004, he was appointed full professor at EPFL, where he was dean of the School of Life Sciences until 2012. He also served on the Life Sciences jury for the Infosys Prize in 2010.
Didier Trono (born 1956) is a Swiss virologist and a professor at the École Polytechnique Fédérale de Lausanne (EPFL). He is known for his research on virus-host interactions and the development of lentiviral vectors for gene therapy.
